DelveInsight’s “Alcoholic Hepatitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Alcoholic Hepatitis, historical and forecasted epidemiology as well as the Alcoholic Hepatitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Alcoholic Hepatitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alcoholic Hepatitis Market Forecast
Some of the key facts of the Alcoholic Hepatitis Market Report:
- The Alcoholic Hepatitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- Using the State Inpatient Databases from Florida, Massachusetts, New York, and Washington from 2010 to 2014, Doshi et al. (2020) carried out a retrospective cohort analysis. Patients hospitalised with AH and aged 20 to 79 were included in the research. The bulk of the 56,973 distinct people with AH were male (39,702; 69.7%)
- Since AH presents itself in a broad variety of ways and, in extreme cases, can mimic a bacterial infection and/or biliary blockage, diagnosing the disease can be difficult. Durect Corporation and Novartis are two of the market's top participants.
- Key Alcoholic Hepatitis Companies: Durect Corporation, Novartis, Intercept Pharmaceuticals, Gilead Sciences, PharmaKing, Intercept Pharma, Immuron Ltd., Generon (Shanghai) Corporation Ltd., Sanofi, and others
- Key Alcoholic Hepatitis Therapies: DUR-928, Canakinumab, INT-787, Selonsertib, Canakinumab, MG-1, INT-787, IMM 124-E, and others
- The Alcoholic Hepatitis epidemiology based on gender there are more cases for Alcoholic Hepatitis in males than females
- The Alcoholic Hepatitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Alcoholic Hepatitis pipeline products will significantly revolutionize the Alcoholic Hepatitis market dynamics.
Alcoholic Hepatitis Overview
Alcoholic hepatitis (AH), as the name implies, is an inflammation of the liver brought on by excessive alcohol consumption. Patients frequently have a history of daily alcohol consumption of 8 to 10 drinks. It is typically present in conjunction with fatty liver, an early stage of alcoholic liver disease, and it may aid in the development of cirrhosis by promoting the advancement of fibrosis.
Get a Free sample for the Alcoholic Hepatitis Market Report
https://www.delveinsight.com/report-store/alcoholic-hepatitis-market
Alcoholic Hepatitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Alcoholic Hepatitis Epidemiology Segmentation:
The Alcoholic Hepatitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of Alcoholic Hepatitis
- Prevalent Cases of Alcoholic Hepatitis by severity
- Gender-specific Prevalence of Alcoholic Hepatitis
- Diagnosed Cases of Episodic and Chronic Alcoholic Hepatitis
Download the report to understand which factors are driving Alcoholic Hepatitis epidemiology trends @ Alcoholic Hepatitis Epidemiology Forecast
Alcoholic Hepatitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alcoholic Hepatitis market or expected to get launched during the study period. The analysis covers Alcoholic Hepatitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Alcoholic Hepatitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Alcoholic Hepatitis Therapies and Key Companies
- DUR-928: Durect Corporation
- Canakinumab: Novartis
- INT-787: Intercept Pharmaceuticals
- Selonsertib: Gilead Sciences
- Canakinumab: Novartis
- MG-1: PharmaKing
- INT-787: Intercept Pharma
- IMM 124-E: Immuron Ltd.
Discover more about therapies set to grab major Alcoholic Hepatitis market share @ Alcoholic Hepatitis Treatment Market
Scope of the Alcoholic Hepatitis Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Alcoholic Hepatitis Companies: Durect Corporation, Novartis, Intercept Pharmaceuticals, Gilead Sciences, PharmaKing, Intercept Pharma, Immuron Ltd, Generon (Shanghai) Corporation Ltd., Sanofi, and others
- Key Alcoholic Hepatitis Therapies: DUR-928, Canakinumab, INT-787, Selonsertib, Canakinumab, MG-1, INT-787, IMM 124-E, and others
- Alcoholic Hepatitis Therapeutic Assessment: Alcoholic Hepatitis current marketed and Alcoholic Hepatitis emerging therapies
- Alcoholic Hepatitis Market Dynamics: Alcoholic Hepatitis market drivers and Alcoholic Hepatitis market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Alcoholic Hepatitis Unmet Needs, KOL’s views, Analyst’s views, Alcoholic Hepatitis Market Access and Reimbursement
To know more about Alcoholic Hepatitis companies working in the treatment market, visit @ Alcoholic Hepatitis Clinical Trials and Therapeutic Assessment
Table of Contents
1. Alcoholic Hepatitis Market Report Introduction
2. Executive Summary for Alcoholic Hepatitis
3. SWOT analysis of Alcoholic Hepatitis
4. Alcoholic Hepatitis Patient Share (%) Overview at a Glance
5. Alcoholic Hepatitis Market Overview at a Glance
6. Alcoholic Hepatitis Disease Background and Overview
7. Alcoholic Hepatitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Alcoholic Hepatitis
9. Alcoholic Hepatitis Current Treatment and Medical Practices
10. Alcoholic Hepatitis Unmet Needs
11. Alcoholic Hepatitis Emerging Therapies
12. Alcoholic Hepatitis Market Outlook
13. Country-Wise Alcoholic Hepatitis Market Analysis (2019–2032)
14. Alcoholic Hepatitis Market Access and Reimbursement of Therapies
15. Alcoholic Hepatitis Market Drivers
16. Alcoholic Hepatitis Market Barriers
17. Alcoholic Hepatitis Appendix
18. Alcoholic Hepatitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
